Brickell Biotech (BBI) Stock Price, News & Analysis

Company Overview

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.77 to $0.93
• 52-Week Range: N/A
• Volume: 31,300 shs
• Average Volume: 206,730 shs
• Market Capitalization: $6.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BBI Stock Analysis - Frequently Asked Questions

How were Brickell Biotech's earnings last quarter?

Brickell Biotech, Inc. (NASDAQ:BBI) posted its earnings results on Thursday, August, 11th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.48) by $1.47. Brickell Biotech had a negative trailing twelve-month return on equity of 156.10% and a negative net margin of 643.48%.

When did Brickell Biotech's stock split?

Brickell Biotech's stock reverse split on the morning of Tuesday, July 5th 2022. The 1-45 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Brickell Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Brickell Biotech investors own include Tonix Pharmaceuticals (TNXP), TherapeuticsMD (TXMD), Alphabet (GOOG), NVIDIA (NVDA), Ocugen (OCGN), Meta Platforms (META) and Tesla (TSLA).

Company Calendar

• Last Earnings: 8/11/2022
• Today: 1/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:BBI
• CUSIP: N/A
• CIK: 819050
• Web: www.brickellbio.com
• Phone: (720) 505-4755
• Fax: 858-646-1150
• Employees: 16
• Year Founded: 2009

Profitability

• EPS (Most Recent Fiscal Year): ($13.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-39,470,000.00
• Net Margins: -643.48%
• Pretax Margin: -643.48%
• Return on Equity: -156.10%
• Return on Assets: -128.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.36
• Quick Ratio: 6.36

Sales & Book Value

• Annual Sales: $4.64 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.75 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,874,000
• Free Float: 2,744,000
• Market Cap: $6.75 million
• Optionable: Not Optionable
• Beta: 0.02